Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-F Emile

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Blood|July 14, 2017
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 studyR-O Casasnovas, L Ysebaert, C Thieblemont, et al.
Pediatrics|October 1, 1996
Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective studyJ L Casanova, S Blanche, J F Emile, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetH Blons, J F Emile, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2020
Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929F Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patientsJ Taieb, R Balogoun, K Le Malicot, et al.
Translational Oncology|December 15, 2021
Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancerR Nicolle, O Gayet, M Bigonnet, et al.
Annales De Pathologie|November 28, 2006
[Recommendations for the management of gastro-intestinal stromal tumors]A Le Cesne, B Landi, S Bonvalot, et al.
Nature Genetics|April 7, 1999
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infectionE Jouanguy, S Lamhamedi-Cherradi, D Lammas, et al.
Medical Oncology (Northwood, London, England)|September 29, 2011
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTsJ F Emile, S Brahimi, J M Coindre, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Blood|July 14, 2017
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 studyR-O Casasnovas, L Ysebaert, C Thieblemont, et al.
Pediatrics|October 1, 1996
Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective studyJ L Casanova, S Blanche, J F Emile, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetH Blons, J F Emile, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2020
Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929F Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patientsJ Taieb, R Balogoun, K Le Malicot, et al.
Translational Oncology|December 15, 2021
Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancerR Nicolle, O Gayet, M Bigonnet, et al.
Annales De Pathologie|November 28, 2006
[Recommendations for the management of gastro-intestinal stromal tumors]A Le Cesne, B Landi, S Bonvalot, et al.
Nature Genetics|April 7, 1999
A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infectionE Jouanguy, S Lamhamedi-Cherradi, D Lammas, et al.
Medical Oncology (Northwood, London, England)|September 29, 2011
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTsJ F Emile, S Brahimi, J M Coindre, et al.
Pageof 12